CA2526428A1 - Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections - Google Patents

Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections Download PDF

Info

Publication number
CA2526428A1
CA2526428A1 CA002526428A CA2526428A CA2526428A1 CA 2526428 A1 CA2526428 A1 CA 2526428A1 CA 002526428 A CA002526428 A CA 002526428A CA 2526428 A CA2526428 A CA 2526428A CA 2526428 A1 CA2526428 A1 CA 2526428A1
Authority
CA
Canada
Prior art keywords
leu
ser
glu
gln
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002526428A
Other languages
English (en)
French (fr)
Inventor
Sidney Pestka
Thomas B. Lavoie
William A. Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pestka Biomedical Laboratories Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2526428A1 publication Critical patent/CA2526428A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002526428A 2003-05-23 2004-05-21 Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections Abandoned CA2526428A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47313403P 2003-05-23 2003-05-23
US60/473,134 2003-05-23
PCT/US2004/016201 WO2005023290A2 (en) 2003-05-23 2004-05-21 Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections

Publications (1)

Publication Number Publication Date
CA2526428A1 true CA2526428A1 (en) 2005-03-17

Family

ID=34272431

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002526428A Abandoned CA2526428A1 (en) 2003-05-23 2004-05-21 Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections

Country Status (8)

Country Link
EP (1) EP1626734A2 (zh)
JP (1) JP2006526022A (zh)
CN (1) CN1832755A (zh)
AU (1) AU2004270102B2 (zh)
CA (1) CA2526428A1 (zh)
IL (1) IL171991A0 (zh)
TW (1) TW200509961A (zh)
WO (1) WO2005023290A2 (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036627A2 (en) * 2000-11-03 2002-05-10 Pbl Biomedical Laboratories Interferons, uses and compositions related thereto
US7956161B2 (en) 2007-04-11 2011-06-07 Pestka Biomedical Laboratories, Inc. Interferons of rhesus and cynomolgus origin and uses thereof
US7625555B2 (en) * 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
DK2544705T3 (en) * 2010-03-12 2016-09-19 Synairgen Res Ltd INTERFERON BETA TO USE IN THE LOWER AIR TRANSMISSION CAUSED BY INFLUENZA
EP3095444A1 (en) 2015-05-20 2016-11-23 Dublin City University A method of treating peripheral inflammatory disease
EP3118215A1 (en) 2015-07-16 2017-01-18 Nuritas Limited Anti-inflammatory peptides, and uses thereof
EP3118216A1 (en) 2015-07-16 2017-01-18 Nuritas Limited Cellular growth and proliferation promoting peptides, and uses thereof
BR112018000660A2 (pt) 2015-07-16 2019-05-14 Nuritas Limited peptídeos anti-inflamatórios e seu uso
EP3117831A1 (en) 2015-07-16 2017-01-18 Nuritas Limited Peptides for use in promoting transport of glucose into skeletal muscle
EP3117830A1 (en) 2015-07-16 2017-01-18 Nuritas Limited Antibacterial peptides, and uses thereof
WO2018014936A1 (en) 2016-07-18 2018-01-25 Nuritas Limited Topical compositions
EP3329905A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Topical cosmetic compositions comprising an oligopeptide against anti-aging of the skin
EP3548058B1 (en) 2016-12-05 2022-06-22 Nuritas Limited Compositions comprising peptide wkdeagkplvk
CN108721603B (zh) * 2017-04-14 2020-11-13 中国医学科学院基础医学研究所 干扰素α-1a在制备用于治疗癌症的药物中的用途
US11760963B2 (en) 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
EP3783012A1 (en) 2019-08-20 2021-02-24 Nuritas Limited An antimicrobial peptide
AU2020334196A1 (en) 2019-08-20 2022-03-03 Nuritas Limited Peptides for treating muscle atrophy
CN114650811A (zh) 2019-09-25 2022-06-21 爱尔兰国立都柏林大学 用于基因疗法的纳米粒子组合物
BR112022007047A2 (pt) 2019-10-22 2022-07-05 Nuritas Ltd Tratamento de doença hepática gordurosa não alcoólica
EP3862014A1 (en) 2020-02-07 2021-08-11 Nuritas Limited Treatment of panx1 associated diseases
CN113425832A (zh) * 2020-03-23 2021-09-24 杭州先为达生物科技有限公司 干扰素λ在新型冠状病毒(2019-nCoV)感染治疗中的应用
WO2021195477A1 (en) * 2020-03-27 2021-09-30 Ketoneaid, Inc. Ketone ester as a therapeutic treatment of covid-19, long covid, and related viral infections
US20230173096A1 (en) * 2020-05-18 2023-06-08 Northwestern University Targeted antiviral drugs
WO2022079205A1 (en) * 2020-10-15 2022-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ifn-alpha polypeptides for the treatment of coronavirus infections
WO2023131648A1 (en) 2022-01-05 2023-07-13 Branca Bunus Limited Nanoparticulate compositions for gene therapy
CN114533706B (zh) * 2022-02-15 2022-10-14 深圳市利云德生物技术有限公司 一种用于防治呼吸道疾病的雾化吸入制剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3891600A (en) * 1999-03-18 2000-10-04 Zymogenetics Inc. Murine interferon-alpha named also zcyto13
JP2003510352A (ja) * 1999-10-01 2003-03-18 インスティチュート オブ モレキュラー アンド セル バイオロジー ウイルス媒介性疾病の治療用化合物
WO2002015664A2 (en) * 2000-08-23 2002-02-28 The New York Hospital Medical Center Of Queens Methods of preventing or treating west nile virus and other infections
WO2002036627A2 (en) * 2000-11-03 2002-05-10 Pbl Biomedical Laboratories Interferons, uses and compositions related thereto

Also Published As

Publication number Publication date
WO2005023290A2 (en) 2005-03-17
WO2005023290A3 (en) 2005-12-22
AU2004270102A1 (en) 2005-03-17
EP1626734A2 (en) 2006-02-22
CN1832755A (zh) 2006-09-13
JP2006526022A (ja) 2006-11-16
TW200509961A (en) 2005-03-16
IL171991A0 (en) 2011-08-01
AU2004270102B2 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
AU2004270102B2 (en) Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
Bhavana et al. COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic
AU2002368202B2 (en) Methods and compositions for therapeutic use of RNA interference
US8309531B2 (en) Administration of interferon for prophylaxis against or treatment of pathogenic infection
US20090304798A1 (en) Methods and compositions for therapeutic use of RNA interference
AU2003257156B2 (en) Cell transport compositions and uses thereof
CN104436170B (zh) 用于药物输送的二酮哌嗪盐
US20150290132A1 (en) Cell Transport Compositions and Uses Thereof
JP6099095B2 (ja) 組換えヒトインターフェロン様タンパク質
JP2013516170A (ja) インターフェロンアナログ
CN108473555A (zh) 条件活性多肽
KR20180037185A (ko) 광범위의 항감염성 펩티드
WO2011017160A1 (en) Mutant human interferon proteins and genes
CA2427850A1 (en) Interferons, uses and compositions related thereto
WO2004019982A1 (ja) 治療薬
KR101941845B1 (ko) 생리활성 물질 전달을 위한 나노 구조체, 이의 이용방법, 및 이의 제조방법
LEHR Nanostructures for overcoming the pulmonary barriers: physiological considerations and mechanistic issues
Raytthatha et al. WORLD JOURNAL OF CURRENT MEDICAL AND PHARMACEUTICAL RESEARCH
Alabsi Synthesis, Comprehensive Characterization, and Development of Therapeutic Peptides and Glycopeptides for Targeted Respiratory Drug Delivery as Inhalation Aerosols
WO2023245176A1 (en) Targeted nanomedicine for treating fibrotic lung disorders
WO2021224264A1 (en) Antipathogen vesicle
Beingessner et al. Bioactive Rosette Nanotubes for Bone Tissue Engineering and Drug Delivery
TUTOR Pulmonary drug delivery systems based on polymeric micro and nanoparticles for the treatment of cystic fibrosis

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued